— The first small molecule drug candidate showing ability to restore memory to normal in Alzheimer’s disease models — PITTSBURGH, Nov. 11, 2016 /PRNewswire/...

PITTSBURGH, Oct. 28, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been...

Focusing on synaptic protection in Alzheimer’s Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule...

“The worst thing about dementia is that you progressively lose the person that you love,” says Anne Tudor, and she knows it first hand. Her partner, Edie Mayhew, 65,...